Avutometinib (VS-6766) + Defactinib (VS-6063)

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Low Grade Serous Ovarian Cancer

Conditions

Low Grade Serous Ovarian Cancer, Ovarian Cancer

Trial Timeline

Oct 30, 2024 → Oct 1, 2027

NCT ID

NCT06682572

About Avutometinib (VS-6766) + Defactinib (VS-6063)

Avutometinib (VS-6766) + Defactinib (VS-6063) is a phase 2 stage product being developed by Verastem Oncology for Low Grade Serous Ovarian Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06682572. Target conditions include Low Grade Serous Ovarian Cancer, Ovarian Cancer.

What happened to similar drugs?

0 of 7 similar drugs in Low Grade Serous Ovarian Cancer were approved

Approved (0) Terminated (1) Active (6)

🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3

❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3

🔄rituximabBiogenPhase 3

🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3

🔄Remestemcel-LMesoblastPhase 3

🔄remestemcel-LMesoblastPhase 3

🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06682572	Phase 2	Active	Oct 30, 2024	Oct 1, 2027	Low Grade Serous Ovarian Cancer

Competing Products

20 competing products in Low Grade Serous Ovarian Cancer

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
azenosertib	Zentalis Pharmaceuticals	Phase 2	32
Sepantronium Bromide	Cothera Bioscience	Phase 2	29
DS-1001b	Daiichi Sankyo	Phase 2	39
Rabeprazole Sodium	Eisai	Pre-clinical	26
Binimetinib 15 MG	Ono Pharmaceutical	Phase 2	42
Abemaciclib + Letrozole	Eli Lilly	Phase 2	42
Pirtobrutinib + Mosunetuzumab	Eli Lilly	Phase 2	42
Pembrolizumab + Pemetrexed + Abemaciclib	Eli Lilly	Phase 1	21
DSP-0390	Sumitomo Pharma	Phase 1	33
Mirvetuximab soravtansine + Carboplatin	AbbVie	Phase 2	39
Mirvetuximab Soravtansine	AbbVie	Phase 2	42
Acalabrutinib + Obinutuzumab	AstraZeneca	Phase 2	42
Olaparib Pill + AZD6738	AstraZeneca	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Efineptakin alfa + Pembrolizumab	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	39
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel	Merck	Phase 2	35
Cilengitide	Merck	Phase 2	31
Avelumab	Merck	Phase 2	35